Methyl helicterate inhibits hepatic stellate cell activation through downregulating the ERK1/2 signaling pathway

Area of Science:

• Hepatology and cell biology
• Molecular mechanisms of liver fibrosis
• Pharmacological inhibition of hepatic stellate cells

Background:

• Liver fibrosis is a pathological process driven by activated hepatic stellate cells (HSCs).
• Platelet-derived growth factor (PDGF) is a key activator of HSCs.
• Understanding the molecular pathways regulating HSC activation is crucial for developing anti-fibrotic therapies.

Purpose of the Study:

• To investigate the inhibitory effect of methyl helicterate (MH) on activated HSCs (HSC-T6).
• To elucidate the underlying mechanism of MH's action against liver fibrosis.
• To determine MH's impact on HSC viability, proliferation, apoptosis, and cell cycle progression.

Main Methods:

• HSC-T6 cells were stimulated with PDGF to induce activation.
• The effects of MH on cell viability, membrane integrity, colony formation, migration, apoptosis, and cell cycle were assessed.
• The activation of the extracellular signal-regulated kinase (ERK1/2) signaling pathway was analyzed.

Main Results:

• MH significantly inhibited HSC-T6 cell viability and proliferation in a dose-dependent manner.
• MH treatment compromised cell membrane integrity, reduced clonogenicity and migration, induced apoptosis, and caused G2 phase cell cycle arrest.
• MH downregulated the expression of ERK1, ERK2, c-fos, c-myc, and Ets-1, effectively blocking the ERK1/2 pathway.

Conclusions:

• Methyl helicterate demonstrates significant anti-fibrotic potential by inhibiting HSC activation.
• MH promotes HSC apoptosis and cell cycle arrest through the downregulation of the ERK1/2 signaling pathway.
• MH represents a promising therapeutic agent for liver fibrosis, targeting key molecular pathways involved in HSC activation.